COMMUNIQUÉS West-GlobeNewswire
-
OSE Immunotherapeutics to Present at Upcoming Investor Conferences
23/03/2026 -
Trinity Biotech Announces Successful Clinical Results for Its Enhanced EpiCapture™ Prostate Cancer Test
23/03/2026 -
Checkerspot Announces Breakthrough, using Microalgae to Produce Palmitoleic Acid Oil at Scale, Opening a New Pathway to Omega-7s
23/03/2026 -
Senti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate Killer Conference
23/03/2026 -
SafeSpace Global Secures Shareholder Approval to Increase Authorized Shares of Common Stock
23/03/2026 -
AdipoPharma Enters Clinic with First-in-Class Therapy Targeting Type 2 diabetes with the potential to maintain muscle mass
23/03/2026 -
Standard Dental Labs Inc. Engages Strategic Advisor to Support Lab Acquisition Strategy
23/03/2026 -
Umoja Biopharma Appoints Dr. Marcela Maus and Dr. Athena Countouriotis to Board of Directors
23/03/2026 -
Cortexa Advances Commercialisation of MDMA Supply in Australia
23/03/2026 -
Siren Biotechnology Announces FDA Clearance of Investigator-Initiated IND to Advance Phase 1 Study in Recurrent High-Grade Glioma
23/03/2026 -
Children’s National launches Division of AI Research to lead the future of artificial intelligence in pediatric medicine
23/03/2026 -
China SXT Pharmaceuticals, Inc. Announces Share Re-classification
23/03/2026 -
Roche inaugurates new research home for the Institute of Human Biology, pioneering human model systems to accelerate drug discovery and development
23/03/2026 -
BioStem Appoints Jodi Ungrodt to Board of Directors as Audit Committee Chair
23/03/2026 -
CareMore Health Announces Appointment of Dr. Anh Pham as Chief Medical Officer
23/03/2026 -
Vantive Accelerates U.S. Home Therapy Transformation With New Digital and Patient Support Innovations
23/03/2026 -
Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services
23/03/2026 -
Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease
23/03/2026 -
Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan of Arrangement
23/03/2026
Pages